- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06133972
Fase 3 forlængelsesundersøgelse til evaluering af langsigtet sikkerhed af Ianalumab hos deltagere med systemisk lupus erythematosus (SIRIUS-SLE forlængelse). (SIRIUS-SLE LTE)
A Randomized, Double-blind, Placebo-controlled Extension Study, Followed by a Study Treatment Withdrawal or Open-label Period, to Assess the Long-term Safety and Tolerability of Ianalumab in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE Extension)
The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The purpose of this extension study is to evaluate long-term safety and tolerability of ianalumab administered s.c. monthly or quarterly, compared to monthly placebo, in adolescent and adult participants with anti-nuclear antibody (ANA)-positive systemic lupus erythematosus of moderate-to-severe disease activity, who have completed either CVAY736F12301 (SIRIUS-SLE 1) or CVAY736F12302 (SIRIUS-SLE 2) core studies.
This extension study will last up to 7 years and includes the following three treatment periods:
- a 3-year double-blind, randomized, placebo-controlled treatment period, evaluating the safety and efficacy of ianalumab or placebo (Period 1);
- followed by a 2-year treatment period evaluating safety and efficacy of treatment withdrawal and open-label ianalumab administered s.c. monthly.
- and an up to 2-year open-label, safety monitoring period (Period 3).
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Udvidet adgang
Kontakter og lokationer
Studiekontakt
- Navn: Novartis Pharmaceuticals
- Telefonnummer: 1-888-669-6682
- E-mail: novartis.email@novartis.com
Undersøgelse Kontakt Backup
- Navn: Novartis Pharmaceuticals
- Telefonnummer: +41613241111
- E-mail: novartis.email@novartis.com
Studiesteder
-
-
-
Caba, Argentina, C1015ABO
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
Caba, Argentina, C1427CCL
- Rekruttering
- Novartis Investigative Site
-
San Miguel de Tucumán, Argentina, T4000AXL
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Buenos Aires
-
La Plata, Buenos Aires, Argentina, B1900AWT
- Rekruttering
- Novartis Investigative Site
-
Quilmes, Buenos Aires, Argentina, 1878
- Rekruttering
- Novartis Investigative Site
-
San Miguel, Buenos Aires, Argentina, B1663GKT
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Tucumán Province
-
San Miguel, Tucumán Province, Argentina, T4000CBC
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
-
-
Queensland
-
Maroochydore, Queensland, Australien, 4558
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Salvador, Brasilien, 40323-010
- Rekruttering
- Novartis Investigative Site
-
-
Espírito Santo
-
Vitória, Espírito Santo, Brasilien, 29055-450
- Rekruttering
- Novartis Investigative Site
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasilien, 40150-150
- Rekruttering
- Novartis Investigative Site
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasilien, 30150-221
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Paraná
-
Curitiba, Paraná, Brasilien, 80030-110
- Rekruttering
- Novartis Investigative Site
-
-
Rio de Janeiro
-
Niterói, Rio de Janeiro, Brasilien, 24020-096
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
Rio de Janeiro, Rio de Janeiro, Brasilien, 22211-230
- Rekruttering
- Novartis Investigative Site
-
-
São Paulo
-
Barretos, São Paulo, Brasilien, 14784-400
- Rekruttering
- Novartis Investigative Site
-
São Paulo, São Paulo, Brasilien, 04038-002
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
São Paulo, São Paulo, Brasilien, 01244-030
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
-
-
-
Sofia, Bulgarien, 1431
- Rekruttering
- Novartis Investigative Site
-
-
Bulgaria
-
Plovdiv, Bulgaria, Bulgarien, 4002
- Rekruttering
- Novartis Investigative Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1L7
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 2S8
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Quebec
-
Rimouski, Quebec, Canada, G5L 5T1
- Rekruttering
- Novartis Investigative Site
-
-
-
-
Los Ríos Region
-
Valdivia, Los Ríos Region, Chile, 5110683
- Rekruttering
- Novartis Investigative Site
-
-
RM
-
Santiago, RM, Chile, 7500588
- Rekruttering
- Novartis Investigative Site
-
-
Santiago Metropolitan
-
Santiago, Santiago Metropolitan, Chile, 7500710
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Bogotá, Colombia, 111211
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Antioquia
-
Medellín, Antioquia, Colombia, 050001
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Atlántico
-
Barranquilla, Atlántico, Colombia, 080020
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Cundinamarca
-
Chía, Cundinamarca, Colombia, 250001
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Santander Department
-
Bucaramanga, Santander Department, Colombia, 680003
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Colombia, 760046
- Rekruttering
- Novartis Investigative Site
-
-
-
-
Alabama
-
Anniston, Alabama, Forenede Stater, 36207
- Rekruttering
- Pinnacle Research Group Llc
-
Ledende efterforsker:
- Vishala L Chindalore
-
Kontakt:
- Ruby Fields
- Telefonnummer: +1 256 236 0055
- E-mail: rfields@pinnacletrials.com
-
-
California
-
Burbank, California, Forenede Stater, 91505
- Rekruttering
- Providence Medical Center
-
Ledende efterforsker:
- Sue Chung
-
Kontakt:
- Sandra Figueroa
- Telefonnummer: +1 818 869 7067
- E-mail: Sandra.Figueroa@providence.org
-
La Palma, California, Forenede Stater, 90623
- Rekruttering
- Advanced Medical Research
-
Ledende efterforsker:
- Gerald Ho
-
Kontakt:
- Reza Azadegan
- Telefonnummer: +1 714 752 6587
- E-mail: razadegan@advmedresearch.com
-
Westlake Village, California, Forenede Stater, 91361
- Aktiv, ikke rekrutterende
- Millennium Clinical Trials
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Rekruttering
- University of Colorado Denver
-
Ledende efterforsker:
- Christopher Striebich
-
Kontakt:
- Chong Pedrick
- E-mail: chong.pedrick@cuanschutz.edu
-
-
Florida
-
Clearwater, Florida, Forenede Stater, 33765
- Rekruttering
- Clinical Res Of W Florida
-
Ledende efterforsker:
- Robert Levin
-
Kontakt:
- Jessica Mayfield
- Telefonnummer: +1 727 466 0078
- E-mail: JMayfield@crwf.com
-
Cooper City, Florida, Forenede Stater, 33024
- Rekruttering
- GNP Research
-
Ledende efterforsker:
- Mark Jaffe
-
Kontakt:
- Melissa Pierce
- Telefonnummer: +1 754 248 3589
- E-mail: melissa@gnpresearch.com
-
Homestead, Florida, Forenede Stater, 33033
- Rekruttering
- Homestead Assoc In Research Inc
-
Ledende efterforsker:
- Gilberto Seco
-
Kontakt:
- Mario Hernandez
- Telefonnummer: 13052460873
- E-mail: mhernandez@associatesinresearch.com
-
Plantation, Florida, Forenede Stater, 33324
- Rekruttering
- IRIS Research and Development
-
Ledende efterforsker:
- Guillermo Valenzuela
-
Kontakt:
- Jhon Galindo
- Telefonnummer: +1 954 476 2338
- E-mail: jgalindo@irisrheumatology.com
-
Tampa, Florida, Forenede Stater, 33603
- Rekruttering
- Clinical Research of West Florida Inc
-
Ledende efterforsker:
- John Carter
-
Kontakt:
- Abby Carlson
- Telefonnummer: +1 813 870 1292
- E-mail: ACarlson@crwf.com
-
-
Georgia
-
Lawrenceville, Georgia, Forenede Stater, 30044
- Rekruttering
- Parris and Associates Rheumatology
-
Ledende efterforsker:
- Glenn Parris
-
Kontakt:
- Mannai Coutermarsh
- Telefonnummer: +17709621616#8334
- E-mail: m.coutermarsh@parrisandassociates.net
-
-
Illinois
-
Skokie, Illinois, Forenede Stater, 60076
- Afsluttet
- Robert A Hozman MD SC
-
Willowbrook, Illinois, Forenede Stater, 60527
- Rekruttering
- Willow Rheumatology Wellness
-
Ledende efterforsker:
- Angela R Crowley
-
Kontakt:
- Lubna Ali
- E-mail: lali@willowrheum.com
-
-
Louisiana
-
Lake Charles, Louisiana, Forenede Stater, 70601
- Rekruttering
- Accurate Clinical Research
-
Ledende efterforsker:
- Enrique Mendez
-
Kontakt:
- Machell Broussard
- E-mail: mbroussard@accurateclinicalresearch.com
-
New Orleans, Louisiana, Forenede Stater, 70112
- Aktiv, ikke rekrutterende
- UMC New Orleans
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21201
- Aktiv, ikke rekrutterende
- University Of Maryland
-
-
Michigan
-
Detroit, Michigan, Forenede Stater, 48202
- Rekruttering
- Henry Ford Health
-
Ledende efterforsker:
- Alireza Meysami
-
Kontakt:
- Jenna Hudy
- Telefonnummer: +1 313 916 1984
- E-mail: jhudy1@hfhs.org
-
Grand Blanc, Michigan, Forenede Stater, 48439
- Rekruttering
- Ahmed Arif Medical Research Center
-
Ledende efterforsker:
- Ali Karrar
-
Kontakt:
- Iman Abdelrahman
- Telefonnummer: +1 810 953 8700
- E-mail: iman@aamrc.net
-
-
Ohio
-
Middleburg Heights, Ohio, Forenede Stater, 44130
- Rekruttering
- Paramount Med Rsrch and Consult LLC
-
Ledende efterforsker:
- Isam Diab
-
Kontakt:
- Denine Ryan
- Telefonnummer: +1 440 891 9395
- E-mail: deniner64@gmail.com
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15213
- Rekruttering
- University Of Pittsburgh
-
Ledende efterforsker:
- Andreea Coca
-
Kontakt:
- Kathryn Lemon
- E-mail: kal128@pitt.edu
-
-
Tennessee
-
Jackson, Tennessee, Forenede Stater, 38305
- Rekruttering
- West Tennessee Research Institute
-
Ledende efterforsker:
- Jacob A Aelion
-
Kontakt:
- Rachel Williams
- Telefonnummer: 17316330119
- E-mail: rwilliams@arthritisclinic.org
-
Memphis, Tennessee, Forenede Stater, 38119
- Rekruttering
- Shelby Research LLC
-
Ledende efterforsker:
- Ramesh C Gupta
-
Kontakt:
- Suvarna Konangula
- Telefonnummer: +1 901 681 9670
- E-mail: shelbyres1999@outlook.com
-
-
Texas
-
Bellaire, Texas, Forenede Stater, 77401
- Rekruttering
- Novel Research LLC
-
Ledende efterforsker:
- Wajeeha Yousaf
-
Kontakt:
- Hassan Khan
- E-mail: khan@novelresearch.net
-
League City, Texas, Forenede Stater, 77573
- Rekruttering
- Accurate Clinical Research
-
Ledende efterforsker:
- Sabeen Najam
-
Kontakt:
- Mariela Martinez
- Telefonnummer: +1 281 422 7179
- E-mail: mmartinez@accurateclinicalresearch.com
-
Red Oak, Texas, Forenede Stater, 75154
- Rekruttering
- Epic Medical Research
-
Ledende efterforsker:
- Sunny Patel
-
Kontakt:
- Harshini Potluri
- Telefonnummer: +1 469 206 2642
- E-mail: hpotluri@epicmedresearch.com
-
-
-
-
-
Montpellier, Frankrig, 34295
- Rekruttering
- Novartis Investigative Site
-
Paris, Frankrig, 75014
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
Paris, Frankrig, 75013
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
Toulouse, Frankrig, 31059
- Rekruttering
- Novartis Investigative Site
-
Toulouse, Frankrig, 31054
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Guatemala City, Guatemala, 01010
- Rekruttering
- Novartis Investigative Site
-
-
Departamento de Guatemala
-
Guatemala City, Departamento de Guatemala, Guatemala, 01010
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
New Delhi, Indien, 110075
- Rekruttering
- Novartis Investigative Site
-
-
Gujarat
-
Ahmedabad, Gujarat, Indien, 380015
- Rekruttering
- Novartis Investigative Site
-
Ahmedabad, Gujarat, Indien, 380006
- Rekruttering
- Novartis Investigative Site
-
-
Kerala
-
Kozhikode, Kerala, Indien, 673008
- Rekruttering
- Novartis Investigative Site
-
-
Maharashtra
-
Kolhāpur, Maharashtra, Indien, 416001
- Rekruttering
- Novartis Investigative Site
-
Nagpur, Maharashtra, Indien, 441108
- Rekruttering
- Novartis Investigative Site
-
Nashik, Maharashtra, Indien, 422101
- Rekruttering
- Novartis Investigative Site
-
Pune, Maharashtra, Indien, 411001
- Rekruttering
- Novartis Investigative Site
-
Pune, Maharashtra, Indien, 411007
- Rekruttering
- Novartis Investigative Site
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, Indien, 110060
- Rekruttering
- Novartis Investigative Site
-
-
New Delhi
-
New Delhi, New Delhi, Indien, 110029
- Rekruttering
- Novartis Investigative Site
-
-
Uttarakhand
-
Dehradun, Uttarakhand, Indien, 248001
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Haifa, Israel, 3109601
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
Ramat Gan, Israel, 5265601
- Rekruttering
- Novartis Investigative Site
-
-
-
-
FE
-
Cona, FE, Italien, 44124
- Rekruttering
- Novartis Investigative Site
-
-
PD
-
Padova, PD, Italien, 35128
- Rekruttering
- Novartis Investigative Site
-
-
PI
-
Pisa, PI, Italien, 56126
- Rekruttering
- Novartis Investigative Site
-
-
RM
-
Roma, RM, Italien, 00152
- Rekruttering
- Novartis Investigative Site
-
-
TO
-
Torino, TO, Italien, 10128
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Miyazaki, Japan, 8891692
- Rekruttering
- Novartis Investigative Site
-
Osaka, Japan, 5458586
- Rekruttering
- Novartis Investigative Site
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 4578510
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
Nagoya, Aichi-ken, Japan, 4578511
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 0608648
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan, 2360004
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Miyagi
-
Sendai, Miyagi, Japan, 9838512
- Rekruttering
- Novartis Investigative Site
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan, 1138519
- Rekruttering
- Novartis Investigative Site
-
Chuo Ku, Tokyo, Japan, 1048560
- Rekruttering
- Novartis Investigative Site
-
Fuchū, Tokyo, Japan, 1838524
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
Shinjuku-ku, Tokyo, Japan, 1608582
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
tabashi City, Tokyo, Japan, 1738610
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
-
-
-
Beijing, Kina, 100730
- Rekruttering
- Novartis Investigative Site
-
Beijing, Kina, 100069
- Rekruttering
- Novartis Investigative Site
-
Shanghai, Kina, 200001
- Rekruttering
- Novartis Investigative Site
-
Xinxiang, Kina, 453099
- Rekruttering
- Novartis Investigative Site
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510080
- Rekruttering
- Novartis Investigative Site
-
Guangzhou, Guangdong, Kina, 510000
- Rekruttering
- Novartis Investigative Site
-
Shantou, Guangdong, Kina, 515000
- Rekruttering
- Novartis Investigative Site
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210008
- Rekruttering
- Novartis Investigative Site
-
Suzhou, Jiangsu, Kina, 215004
- Rekruttering
- Novartis Investigative Site
-
-
Jiangxi
-
Nanchang, Jiangxi, Kina, 330006
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
Pingxiang, Jiangxi, Kina, 337000
- Rekruttering
- Novartis Investigative Site
-
-
Jilin
-
Changchun, Jilin, Kina, 130021
- Rekruttering
- Novartis Investigative Site
-
-
Shandong
-
Linyi, Shandong, Kina, 276100
- Rekruttering
- Novartis Investigative Site
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610041
- Rekruttering
- Novartis Investigative Site
-
-
Xinjiang
-
Ürümqi, Xinjiang, Kina, 830001
- Rekruttering
- Novartis Investigative Site
-
-
Zhejiang
-
Ningbo, Zhejiang, Kina, 315016
- Rekruttering
- Novartis Investigative Site
-
Wenzhou, Zhejiang, Kina, 325000
- Rekruttering
- Novartis Investigative Site
-
-
-
-
Perak
-
Ipoh, Perak, Malaysia, 30450
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
México, Mexico, 07760
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Guanajuato
-
León, Guanajuato, Mexico, 37160
- Rekruttering
- Novartis Investigative Site
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44160
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Mexico City
-
Mexico City, Mexico City, Mexico, 06700
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Michoacán
-
Morelia, Michoacán, Mexico, 58000
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Yucatán
-
Mérida, Yucatán, Mexico, 97070
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Bydgoszcz, Polen, 85-065
- Rekruttering
- Novartis Investigative Site
-
Bydgoszcz, Polen, 85-168
- Rekruttering
- Novartis Investigative Site
-
Bytom, Polen, 41 902
- Rekruttering
- Novartis Investigative Site
-
Warsaw, Polen, 00-874
- Rekruttering
- Novartis Investigative Site
-
Warsaw, Polen, 04-141
- Rekruttering
- Novartis Investigative Site
-
-
Lower Silesian Voivodeship
-
Wroclaw, Lower Silesian Voivodeship, Polen, 52-210
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Braga, Portugal, 4710-243
- Rekruttering
- Novartis Investigative Site
-
Lisbon, Portugal, 1050-034
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Brasov, Rumænien, 500283
- Rekruttering
- Novartis Investigative Site
-
Bucharest, Rumænien, 011172
- Rekruttering
- Novartis Investigative Site
-
-
Cluj
-
Cluj-Napoca, Cluj, Rumænien, 400006
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Bratislava, Slovakiet, 811 08
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
Košice, Slovakiet, 040 01
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Spanien, 08035
- Rekruttering
- Novartis Investigative Site
-
Madrid, Spanien, 28034
- Rekruttering
- Novartis Investigative Site
-
Valencia, Spanien, 46014
- Rekruttering
- Novartis Investigative Site
-
-
A Coruna
-
Santiago Compostela, A Coruna, Spanien, 15706
- Rekruttering
- Novartis Investigative Site
-
-
Barcelona
-
Badalona, Barcelona, Spanien, 08916
- Rekruttering
- Novartis Investigative Site
-
-
Cantabria
-
Santander, Cantabria, Spanien, 39008
- Rekruttering
- Novartis Investigative Site
-
-
Catalonia
-
Barcelona, Catalonia, Spanien, 08003
- Rekruttering
- Novartis Investigative Site
-
-
Madrid
-
San Sebastian Reyes, Madrid, Spanien, 28702
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Umhlanga, Sydafrika, 4320
- Rekruttering
- Novartis Investigative Site
-
-
Gauteng
-
Pretoria, Gauteng, Sydafrika, 0002
- Rekruttering
- Novartis Investigative Site
-
-
Western Cape
-
Cape Town, Western Cape, Sydafrika, 7500
- Rekruttering
- Novartis Investigative Site
-
Cape Town, Western Cape, Sydafrika, 7405
- Rekruttering
- Novartis Investigative Site
-
Somerset West, Western Cape, Sydafrika, 7130
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Gwangju, Sydkorea, 61469
- Afsluttet
- Novartis Investigative Site
-
Seoul, Sydkorea, 06591
- Rekruttering
- Novartis Investigative Site
-
Seoul, Sydkorea, 04763
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Kaohsiung City, Taiwan, 833
- Rekruttering
- Novartis Investigative Site
-
Taichung, Taiwan, 40447
- Rekruttering
- Novartis Investigative Site
-
Taichung, Taiwan, 407219
- Rekruttering
- Novartis Investigative Site
-
Taipei, Taiwan, 10002
- Rekruttering
- Novartis Investigative Site
-
Taipei, Taiwan, 11217
- Rekruttering
- Novartis Investigative Site
-
Taoyuan, Taiwan, 33305
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Bangkok, Thailand, 10400
- Rekruttering
- Novartis Investigative Site
-
Bangkok, Thailand, 10700
- Rekruttering
- Novartis Investigative Site
-
-
Hat Yai
-
Songkhla, Hat Yai, Thailand, 90110
- Rekruttering
- Novartis Investigative Site
-
-
Thailand
-
Muang, Thailand, Thailand, 12120
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Brno, Tjekkiet, 638 00
- Rekruttering
- Novartis Investigative Site
-
Prague, Tjekkiet, 128 00
- Rekruttering
- Novartis Investigative Site
-
Uherské Hradiště, Tjekkiet, 686 01
- Rekruttering
- Novartis Investigative Site
-
-
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Tyskland, 50937
- Trukket tilbage
- Novartis Investigative Site
-
-
Saxony
-
Leipzig, Saxony, Tyskland, 04103
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Budapest, Ungarn, 1134
- Rekruttering
- Novartis Investigative Site
-
Gyula, Ungarn, 5700
- Rekruttering
- Novartis Investigative Site
-
Zalaegerszeg, Ungarn, 8900
- Rekruttering
- Novartis Investigative Site
-
-
Fejér
-
Székesfehérvár, Fejér, Ungarn, 8000
- Rekruttering
- Novartis Investigative Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
- Signed informed consent prior to participation in the extension study. Parent or legal guardian's signed informed consent and child's assent, if appropriate, are required before any assessment is performed for participants <18 years of age. Of note, if the participant reaches age of consent (age as per local law) during the study, they will also need to sign the corresponding study Informed Consent Form (ICF) at the next study visit.
- Participants must have participated in either one of the two SIRIUS-SLE core studies, CVAY736F12301 or CVAY736F12302, and have completed the treatment period through Week 60 without treatment discontinuation.
- In the judgement of the investigator, participants must be expected to clinically benefit from continued study treatment.
Key Exclusion Criteria:
- Use of prohibited therapies.
- Active viral, bacterial or other infections requiring intravenous or intramuscular treatment for clinically significant infection which in the opinion of the investigator will place the participant at risk for participation.
- Plans for administration of live vaccines during the study period.
- Pregnant or nursing (lactating) women.
Other protocol-defined inclusion/exclusion criteria may apply.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Ianalumab monthly
Ianalumab s.c. monthly |
Ianalumab s.c. monthly Ianalumab s.c. quarterly
Andre navne:
|
|
Eksperimentel: Ianalumab quarterly
Ianalumab s.c. quarterly |
Ianalumab s.c. monthly Ianalumab s.c. quarterly
Andre navne:
|
|
Placebo komparator: Placebo monthly
Placebo s.c. monthly |
Placebo s.c. monthly |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of treatment-emergent Adverse events/Serious Adverse events
Tidsramme: through study completion, up to approximately 324 weeks
|
Assessment of long-term safety and tolerability of ianalumab |
through study completion, up to approximately 324 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of participants who achieved Systemic Lupus Erythematosus Responder Index -4 (SRI-4) response
Tidsramme: up to Week 324
|
SRI-4 response is defined as:
|
up to Week 324
|
|
Proportion of participants who achieved Definition of Remission in SLE (DORIS) response
Tidsramme: up to Week 324
|
DORIS is defined as:
|
up to Week 324
|
|
Change in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index
Tidsramme: up to Week 324
|
SLICC/ACR Damage Index is a measure of cumulative damage due to SLE |
up to Week 324
|
|
Average daily dose of corticosteroids administered
Tidsramme: up to Week 324
|
Evaluating the effect of ianalumab on corticosteroids intake |
up to Week 324
|
|
Annualized BILAG moderate or severe flare rate
Tidsramme: up to Week 324
|
Annualized BILAG moderate or severe flare rate where moderate BILAG flare is defined as 2 or more new BILAG-2004 B items, and severe BILAG flare is defined as 1 or more new BILAG-2004 A items, compared to the previous visit |
up to Week 324
|
|
Ianalumab serum concentrations during treatment and follow-up after last dose
Tidsramme: up to Week 324
|
To characterize the Pharmacokinetics (PK) of ianalumab |
up to Week 324
|
|
Incidence and titer of anti-ianalumab antibodies in serum (ADA assay) over time.
Tidsramme: up to Week 324
|
To characterize the immunogenicity of ianalumab |
up to Week 324
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CVAY736F12301E1
- 2023-505929-14-00 (Registry Identifier: EU CT NUMBER)
- 2023 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .